跳至主要内容
临床试验/NCT04592497
NCT04592497Unknown不适用

Evaluation of the Safety and Performance of the Very High Power-Short Duration QDOT Strategy in Patients Referred for Atrial Fibrillation Ablation.

Tel-Aviv Sourasky Medical Center1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年10月15日最近更新:
适应症

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
isolation efficacy

研究概览

简要总结

The aim of the present study is to compare the safety and short-term performance between THERMOCOOL SMARTTOUCH SF-5D QDOT system used with fast ablation mode and the standard Thermocool Smartouch SF in treatment of patients with atrial fibrillation (AF).

详细描述

The very high power-short duration (vHPSD) catheter, is a novel CF catheter optimized for temperature-controlled ablation with microelectrodes and 6 thermocouples for real-time temperature monitoring during ablation. The associated vHPSD algorithm modulates power to maintain target temperature during these vHPSD lesions (90 W, 4 s). In preclinical models, vHPSD ablation with this novel catheter has improved atrial linear lesion contiguity, transmurality, and durability and has substantially reduced radiofrequency ablation times, but with a safety profile similar to those of standard irrigated radiofrequency ablation catheters.

The QDOT -FAST study demonstrated the clinical feasibility and safety of vHPSD ablation. Procedure and fluoroscopy times were substantially lower than historical standard ablation with point-by-point catheters.

The aim of the present study is to compare the safety and short-term performance between THERMOCOOL SMARTTOUCH SF-5D QDOT system used with fast ablation mode and the standard Thermocool Smartouch SF in treatment of patients with atrial fibrillation (AF).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female >18 years old.
  • Subjects must provide written informed consent to participate in the study.
  • Subject is willing to comply with the protocol requirements and return to the treatment center for all required clinical evaluations.

排除标准

  • Pregnant women.
  • Patients with iodine contrast media allergy
  • Patients with renal failure (GFR <60ml/min)

结局指标

主要结局

isolation efficacy

时间窗: 1 day

The first time pulmonary vein isolation (percentages of success)

procedure time

时间窗: 1 day

The procedural and fluoroscopy time required for the procedure (in minutes).

Recurrence of AF

时间窗: 1 year

Recurrence of AF (will be assessed by Holter monitoring)

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

michal roll

PI

Tel-Aviv Sourasky Medical Center

研究点 (1)

Loading locations...

相似试验

Evaluation of the Safety and Performance of the Very... | 临床试验